These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31342312)

  • 21. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Markers in Triple-Negative Breast Cancer.
    Sporikova Z; Koudelakova V; Trojanec R; Hajduch M
    Clin Breast Cancer; 2018 Oct; 18(5):e841-e850. PubMed ID: 30146351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 27. Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
    Guo J; Gong G; Zhang B
    Oncol Rep; 2017 Oct; 38(4):2219-2228. PubMed ID: 28849078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.
    Malfatti MC; Gerratana L; Dalla E; Isola M; Damante G; Di Loreto C; Puglisi F; Tell G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):309. PubMed ID: 31307523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence.
    Fournier MV; Goodwin EC; Chen J; Obenauer JC; Tannenbaum SH; Brufsky AM
    Sci Rep; 2019 Oct; 9(1):14863. PubMed ID: 31619719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel prognostic two-gene signature for triple negative breast cancer.
    Alsaleem MA; Ball G; Toss MS; Raafat S; Aleskandarany M; Joseph C; Ogden A; Bhattarai S; Rida PCG; Khani F; Davis M; Elemento O; Aneja R; Ellis IO; Green A; Mongan NP; Rakha E
    Mod Pathol; 2020 Nov; 33(11):2208-2220. PubMed ID: 32404959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
    Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
    Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic features of rapid versus late relapse in triple negative breast cancer.
    Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
    BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unveiling Role of MicroRNAs as Treatment Strategy and Prognostic Markers in Triple Negative Breast Cancer.
    Balkrishna A; Mittal R; Arya V
    Curr Pharm Biotechnol; 2020; 21(15):1569-1575. PubMed ID: 32593278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
    Naorem LD; Muthaiyan M; Venkatesan A
    J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.